These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 2679367)

  • 1. Extended-spectrum beta-lactamases.
    Philippon A; Labia R; Jacoby G
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1131-6. PubMed ID: 2679367
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydrolysis of beta-lactamase-stable beta-lactams by type I 'sponge' beta-lactamases.
    White AJ; Curtis NA
    J Antimicrob Chemother; 1985 Sep; 16(3):403-5. PubMed ID: 3877042
    [No Abstract]   [Full Text] [Related]  

  • 3. A guide to the relative susceptibilities of beta-lactam antibiotics to beta-lactamases.
    Waley SG
    J Antimicrob Chemother; 1989 Jul; 24(1):87-9. PubMed ID: 2789213
    [No Abstract]   [Full Text] [Related]  

  • 4. Do CTX-M beta-lactamases hydrolyse ertapenem?
    Girlich D; Poirel L; Nordmann P
    J Antimicrob Chemother; 2008 Nov; 62(5):1155-6. PubMed ID: 18662942
    [No Abstract]   [Full Text] [Related]  

  • 5. Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria.
    Pechère JC; Letarte R; Guay R; Asselin C; Morin C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():123-32. PubMed ID: 6977528
    [No Abstract]   [Full Text] [Related]  

  • 6. Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.
    Babini GS; Yuan M; Livermore DM
    Antimicrob Agents Chemother; 1998 May; 42(5):1168-75. PubMed ID: 9593145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodology for the study of beta-lactamases.
    Bush K; Sykes RB
    Antimicrob Agents Chemother; 1986 Jul; 30(1):6-10. PubMed ID: 3530125
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta-lactamase activity of Mycobacterium fortuitum.
    Fattorini L; Amicosante G; Oliva B; Oratore A; Orefici G
    Chemioterapia; 1987 Jun; 6(2 Suppl):204-6. PubMed ID: 3509935
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of beta-lactamases against beta-lactams.
    Stratton CW
    J Antimicrob Chemother; 1988 Jul; 22 Suppl A():23-35. PubMed ID: 3062002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New broad-spectrum beta-lactamases].
    Fernández de Aránguiz A
    Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):511-3. PubMed ID: 1489789
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro antibacterial activity of Sch 34343 and its stability to beta-lactamases and renal dehydropeptidase 1.
    Matsuda K; Sasaki K; Inoue K; Kondo H; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1985 Nov; 28(5):684-8. PubMed ID: 3879159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic diversity of beta-lactamases.
    Frère JM; Dubus A; Galleni M; Matagne A; Amicosante G
    Biochem Soc Trans; 1999 Feb; 27(2):58-63. PubMed ID: 10093707
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of beta-lactamases on the development of novel antimicrobial agents.
    Bush K
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1284-90. PubMed ID: 12498001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomenclature of TEM beta-lactamases.
    Bush K; Jacoby G
    J Antimicrob Chemother; 1997 Jan; 39(1):1-3. PubMed ID: 9044020
    [No Abstract]   [Full Text] [Related]  

  • 15. Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition.
    Barry AL; Jones RN; Wilson HW; Badal RE; Thornsberry C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():97-112. PubMed ID: 6977536
    [No Abstract]   [Full Text] [Related]  

  • 16. [Beta-lactamase inhibitors].
    Nishiya H; Kunii O
    Nihon Rinsho; 1991 Sep; 49(9):2046-51. PubMed ID: 1960873
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential evolution of hydrolysis spectrum for AmpC beta-lactamase of Escherichia coli.
    Le Turnier S; Nordmann P; Eb F; Mammeri H
    J Antimicrob Chemother; 2009 Jan; 63(1):216-8. PubMed ID: 18957396
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk factors and outcome in extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia.
    Blot S; Memon JI
    Saudi Med J; 2009 Oct; 30(10):1366-7; author reply1366-7. PubMed ID: 19838454
    [No Abstract]   [Full Text] [Related]  

  • 19. Extended-spectrum beta-lactamases (ESBL).
    Dandekar PK; Quintiliani R; Nightingale CH; Nicolau DP
    Conn Med; 2002 Jan; 66(1):13-5. PubMed ID: 11852734
    [No Abstract]   [Full Text] [Related]  

  • 20. Redefining extended-spectrum beta-lactamases: balancing science and clinical need.
    Giske CG; Sundsfjord AS; Kahlmeter G; Woodford N; Nordmann P; Paterson DL; Cantón R; Walsh TR
    J Antimicrob Chemother; 2009 Jan; 63(1):1-4. PubMed ID: 18957393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.